x Health Men's Health Children's Health Nutrition and Wellness Reproductive Health Health & Science Digital News Videos Opinions Cartoons Education E-Paper Lifestyle & Entertainment Nairobian Entertainment Eve Woman Travelog TV Stations KTN Home KTN News BTV KTN Farmers TV Radio Stations Radio Maisha Spice FM Vybez Radio Enterprise BULK SMS E-Learning Digger Classified The Standard Group Corporate Contact Us Rate Card Vacancies DCX O.M Portal Corporate Email RMS
Login ×
BTV
VAS
DCX
RMS

Single dose Covid-19 shot now a possibility

Health & Science - By Mercy Kahenda | January 28th 2021 at 12:00:00 GMT +0300

According to researchers, the vaccine may cause mild to moderate side effects associated with any type of vaccination. [File, Standard]

There is a silver lining in the fight against the Covid-19 pandemic after Johnson & Johnson Company moved to seek approval of emergency use for a single-dose vaccine.

The news comes when Kenya is taking part in the AstraZeneca-the University of Oxford developed ChAdOx (AZD1222) vaccine through the Kenya Medical Research Institute-Wellcome Trust in Kilifi.

The Covid-19 vaccine candidate (JNJ-78436735) developed by Janssen Pharmaceutical Companies of Johnson & Johnson, is at Phase 3 of the clinical trial.

Appropriate timing

According to Johnson & Johnson, the timing for approval of the vaccine is appropriate.

“The Company anticipates announcing top-line Phase 3 data for its single-dose Janssen Covid-19 vaccine candidate in late January 2021,” reads a statement published on the Johnson & Johnson website on Tuesday.

If the single-dose vaccine is found to be effective, the company will apply for an emergency use authorisation to the US Food and Drug Administration, among other regulatory bodies, for it to be made subsequently.

Whereas other vaccines are also on trial across the globe, researchers in the study have revealed that the JNJ-78436735 would be easier to administer.

The dose will also reach out to more people. For example, 500 doses will be administered to 500 people.

Findings of the vaccine that brought about 40,000 participants were published in the New England Journal Medicine on January 13, 2021.

During trial, the vaccine was found to provide an immune response that lasted at least 71 days among participants in the age brackets of 18 and 55.

The study demonstrated that after a single vaccination, neutralising antibodies against Covid-19 were detected in more than 90 per cent of participants, at day 29.

The antibodies in the study findings are expected to stop SARS-CoV-2 from infecting the cells.

Researchers noted the safety and immunogenicity profiles of Ad26.COV2. S supported further development of the Johnson & Johnson vaccine.

Neutralising antibodies

Participants involved in the developed neutralising antibodies after two months that stayed in the body for 71 days.

“The Phase 1/2a interim analysis showed that the Company’s Covid-19 vaccine candidate induced an immune response and was generally well-tolerated across all study participants,” read a statement by the company.

However, according to researchers, the vaccine may cause mild to moderate side effects associated with any type of vaccination.

The side effects are similar to those expected from Pfizer and Moderna vaccines, which include headache, body aches, and fever at the injection site.

Be The First To Comment

Top Stories

Kenya receives Covid-19 vaccines
Health & Science - By Standard Team


How borehole water hurts your health
Health & Science - By Gatonye Gathura


Does it matter what cooking oil you use?
Health & Science - By Nancy Nzalambi


Plane carrying Kenya's first batch of Covid-19 vaccines en route to JKIA
Health & Science - By Mireri Junior


Reluctance in uptake of Covid-19 vaccine
Health & Science - By Mercy Kahenda


Covid vaccines: Why this is an injection of politics
Health & Science - By Allan Mungai


One million doses of Covid-19 vaccine arrive on Tuesday
Health & Science - By Mercy Kahenda


Never say die: Woman vows to keep on trying after losing 8 babies
Health & Science - By Yvonne Kawira


Latest Stories

Reluctance in uptake of Covid-19 vaccine
Health & Science - By Mercy Kahenda


Kenya receives Covid-19 vaccines
Health & Science - By Standard Team


Covid vaccines: Why this is an injection of politics
Health & Science - By Allan Mungai


People to watch in the distribution of Covid-19 jab
Health & Science - By Mercy Kahenda


WHO: One in four people will have hearing problems by 2050
Health & Science - By AFP


Plane carrying Kenya's first batch of Covid-19 vaccines en route to JKIA
Health & Science - By Mireri Junior


Four succumb to Covid-19 as Kenya records 345 positive cases
Health & Science - By Jael Mboga


Three signs of a narcissistic father
Health & Science - By Rubie Miseda


Our kidneys are failing but we want to be mums
Health & Science - By Gatonye Gathura


How borehole water hurts your health
Health & Science - By Gatonye Gathura


//

Stay Ahead!

Access premium content only available
to our subscribers.

Or Login With Your Standard Account
Support independent journalism
×
Create An Account
Support independent journalism
I have an account Log in
Reset Password
Support independent journalism
Log in